Oral administration of PLGA-encapsulated CpG ODN and Campylobacter jejuni lysate reduces cecal colonization by Campylobacter jejuni in chickens

• Published in: Vaccine Vol. 36; no. 3; pp. 388 - 394
• Main Authors: Taha-Abdelaziz, Khaled, Hodgins, Douglas C., Alkie, Tamiru Negash, Quinteiro-Filho, Wanderely, Yitbarek, Alexander, Astill, Jake, Sharif, Shayan
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 08-01-2018; Elsevier Limited
• Subjects: Antigens; Antimicrobial agents; Bacteria; Bacterial infections; Campylobacter; Campylobacter jejuni; Campylobacteriosis; Cecum; Chicken; Chickens; Colonization; CpG islands; CpG ODN; Encapsulation; Foodborne diseases; Immune system; Immunoglobulin G; Immunology; Infections; Influenza; Intestine; Life span; Ligands; Nanoparticle; Nanoparticles; Oligonucleotides; Oral administration; Pathogens; PLGA; Polylactide-co-glycolide; Poultry; Proteins; Salmonella; Toll-like receptor ligand; Vaccines; Chicken; PLGA; CpG ODN; Nanoparticle; Toll-like receptor ligand; Campylobacter
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2017.11.073

•Oral administration of CpG ODN significantly reduces Campylobacter colonization.•PLGA NPs formulations enhance the ability of CpG ODN to reduce Campylobacter load.•C. jejuni lysate is capable of reducing the intestinal burden of Campylobacter.•PLGA-encapsulated CpG ODN or C. jejuni lysate could be a promising strategy for control of C. jejuni in chickens.
Campylobacter jejuni (C. jejuni) is a major cause of bacterial food-borne illness in humans. It is considered a commensal organism of the chicken gut and infected chickens serve as a reservoir and shed bacteria throughout their lifespan. Contaminated poultry products are considered the major source of infection in humans. Therefore, to reduce the risk of human campylobacteriosis, it is essential to reduce the bacterial load in poultry products. The present study aimed to evaluate the protective effects of soluble and PLGA-encapsulated oligodeoxynucleotides (ODN) containing unmethylated CpG motifs (E-CpG ODN) as well as C. jejuni lysate as a multi-antigen vaccine against colonization with C. jejuni. The results revealed that oral administration of a low (5 µg) or high (50 µg) dose of CpG resulted in a significant reduction in cecal C. jejuni colonization by 1.23 and 1.32 log10 (P < .05) in layer chickens, respectively, whereas E-CpG significantly reduced cecal C. jejuni colonization by 1.89 and 1.46 log10 in layer and broiler chickens at day 22 post-infection (slaughter age in broilers), respectively. Similar patterns were observed for C. jejuni lysate; oral administration of C. jejuni lysate reduced the intestinal burden of C. jejuni in layer and broiler chickens by 2.24 and 2.14 log10 at day 22 post-infection, respectively. Moreover, the combination of E-CpG and C. jejuni lysate reduced bacterial counts in cecal contents by 2.42 log10 at day 22 post-infection in broiler chickens. Anti-C. jejuni IgG antibody (Ab) titers were significantly higher for broiler chickens receiving a low or high dose of E-CpG or a low dose of C. jejuni lysate than for chickens receiving the placebo. Furthermore, a positive correlation was observed between serum IgG Ab titers and cecal counts of C. jejuni in these groups. These findings suggest that PLGA-encapsulated CpG or C. jejuni lysate could be a promising strategy for control of C. jejuni in chickens.